Results 11 to 20 of about 5,158 (194)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

EClinicalMedicine, 2023
Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in ...
Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal   +14 more
doaj   +1 more source

Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report

Frontiers in Oncology, 2022
Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer.
Hélène Houssiau, Francois P. Duhoux, Didier François, Emmanuel Seront   +3 more
doaj   +1 more source

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan

Journal of the Formosan Medical Association, 2022
Background: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical that confers a survival benefit in patients with confirmed bone-metastatic, castration-resistant prostate cancer with no visceral metastases.
Wei-Chun Weng, Li-Hua Huang, Neng-Chuan Tseng, Yen-Chuan Ou   +3 more
doaj   +1 more source

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study

Cancer Medicine, 2023
Background Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in ...
Anniina Hyväkkä, Okko‐Sakari Kääriäinen, Tapio Utriainen, Eliisa Löyttyniemi, Kalle Mattila, Petri Reinikainen, Jorma Sormunen, Minna Jääskeläinen, Päivi Auvinen, Heikki Minn, Maria Sundvall   +10 more
doaj   +1 more source

Radium 223 dichloride for prostate cancer treatment

Drug Design, Development and Therapy, 2017
Emmanuel Deshayes,1,2 Mathieu Roumiguie,3 Constance Thibault,4 Philippe Beuzeboc,5 Florent Cachin,6 Christophe Hennequin,7 Damien Huglo,8 François Rozet,9 Diana Kassab-Chahmi,10 Xavier Rebillard,11 Nadine Houédé1,12 1Radiobiology ...
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N   +10 more
doaj   +6 more sources

Ocular complications with the use of radium-223: a case series

Radiation Oncology, 2022
Background Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life.
Julie R. Bloom, Alexandra G. Castillejos, Brianna Jones, Nimesh Patel, Barry S. Rosenstein, Richard G. Stock   +5 more
doaj   +1 more source

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Frontiers in Pharmacology, 2022
Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic ...
Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma   +5 more
doaj   +1 more source

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment

Diagnostics, 2023
(1) Background: Prostate cancer is the second most common cancer in men, with androgen suppression as the standard treatment. Despite initially responding to castration, most metastatic prostate cancer patients eventually experience progression. In these
Elisabet Cantó, Georgia Anguera, Natalia Jiménez, Begoña Mellado, Ona Ramírez, Anais Mariscal, Pablo Maroto, Silvia Vidal   +7 more
doaj   +1 more source

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Urology Case Reports, 2020
Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223.
Masato Dobashi, Dai Kouguchi, Yukiko Kanetsuna, Junichiro Ishii   +3 more
doaj   +1 more source

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

Journal of the Formosan Medical Association, 2017
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC).
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang   +10 more
doaj   +1 more source